KR960000921A - 칼시토닌 유도체 및 그 용도 - Google Patents
칼시토닌 유도체 및 그 용도 Download PDFInfo
- Publication number
- KR960000921A KR960000921A KR1019950016580A KR19950016580A KR960000921A KR 960000921 A KR960000921 A KR 960000921A KR 1019950016580 A KR1019950016580 A KR 1019950016580A KR 19950016580 A KR19950016580 A KR 19950016580A KR 960000921 A KR960000921 A KR 960000921A
- Authority
- KR
- South Korea
- Prior art keywords
- thr
- present
- phe
- calcitonin
- amino acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/585—Calcitonins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
1. 청구범위에 기재된 발명이 속한 기술분야
본 발명은 칼시토닌 유도체의 폴리펩티드 및 그 용도에 관한 것이다.
2. 발명이 해결하려고 하는 기술적 과제
칼시토닌 유도체를 유효성분으로 하는 칼슘 대사계 질환의 예방 및 치료제를 제공하는 데 있다.
3. 본 발명의 해결방법의 요지
본 발명에 의한 칼시토닌 유도체는 아미노산 배열(배열번호 2에 해당)이, Cys-Gly-Asn-Leu--Thr-Cys-Met-Leu--Thr-Tyr-Thr-Gln--Phe-Asn-Lsy-Phe--Thr-Phe-Pro-Gln-Thr-Ala-Ile-Gly-Val--Ala-Pro·NH2이고 상기 배열중에 있어서, Hse·NH2는 아미드화된 호모세린 잔기를 의미하며 제1번과 제7번의 CyS 잔기가 디설피드결합으로 연결되어 있다.
4. 본 발명의 중요한 용도
본 발명은 칼슘대사계 질환의 예방 및 치료제의 유효성분으로서 사용하기에 극히 우수하다.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (3)
- 아미노산 배열(배열번호 2에 해당)이, (상기의 배열중에 있어서, Hse·NH2는 아미드화된 호모세린 잔기를 의미하며 제1번과 제7번의 CyS 잔기가 디설피드결합으로 연결되어 있음)인 것을 특징으로 하는 칼시토닌유도체.
- 제1항에 있어서, 비독성 약제 운반체 또는 보형약과 관련하여 상기 아미노산배열을 갖는 칼시토닌유도체의 유효량으로 구성되는 혈중 칼슘농도를 감소시키기 위한 약제의 조성.
- 제1항에 있어서, 비독성 약제 운반체 또는 보형약과 관련하여 상기 아미노산배열을 갖는 칼시토닌유도체의 유효량을 치료시 필요한 투약으로 구성하는 혈중 칼슘농도를 감소시키기 위한 방법.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP94-138618 | 1994-06-21 | ||
JP6138618A JPH083196A (ja) | 1994-06-21 | 1994-06-21 | カルシトニン誘導体及びその用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
KR960000921A true KR960000921A (ko) | 1996-01-25 |
Family
ID=15226293
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019950016580A KR960000921A (ko) | 1994-06-21 | 1995-06-21 | 칼시토닌 유도체 및 그 용도 |
Country Status (5)
Country | Link |
---|---|
US (1) | US5536812A (ko) |
EP (1) | EP0694561A1 (ko) |
JP (1) | JPH083196A (ko) |
KR (1) | KR960000921A (ko) |
CN (1) | CN1120549A (ko) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6085599A (en) * | 1995-04-26 | 2000-07-11 | Feller; Murray F. | Magnetic flow sensor |
CN1064051C (zh) * | 1997-04-30 | 2001-04-04 | 中国人民解放军军事医学科学院毒物药物研究所 | 不含二硫键的鲑鱼和鳗鱼降钙素类似物及其制备方法 |
AU4401097A (en) * | 1997-09-18 | 1999-04-05 | Hyundai Pharm. Ind. Co., Ltd. | Amino acid derivatives |
US6417249B1 (en) | 1997-10-31 | 2002-07-09 | Hewlett-Packard Company | Ink-jet printing ink compositions having superior smear-fastness |
US5948978A (en) * | 1998-07-14 | 1999-09-07 | Feller; Murray F. | Induction heated mass flow sensor |
US6508134B1 (en) | 1999-09-01 | 2003-01-21 | Murray F. Feller | Transit-time flow sensor-frequency mode |
AU2010206614B2 (en) | 2009-01-22 | 2015-03-26 | Keybioscience Ag | Treatment for obesity |
AU2010223329B2 (en) | 2009-03-12 | 2016-07-21 | Keybioscience Ag | Treatment of diabetes and metabolic syndrome |
US9533022B2 (en) | 2011-11-02 | 2017-01-03 | KeyBioscience A/S | Peptide analogs for treating diseases and disorders |
AU2012332265B2 (en) | 2011-11-02 | 2016-11-10 | Keybioscience Ag | Peptide analogs for treating diseases and disorders |
CN106880835A (zh) * | 2017-02-17 | 2017-06-23 | 云南同方科技有限公司 | 用于缓解高血压症状的植物精油复合物制备及应用 |
CN106880834A (zh) * | 2017-02-17 | 2017-06-23 | 云南同方科技有限公司 | 一种用于缓解高血压症状的植物精油复合物及制备方法 |
JP7255423B2 (ja) * | 2019-08-23 | 2023-04-11 | 株式会社島津製作所 | 分析用試料の調製方法、分析方法および分析用試料の調製用キット |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4652627A (en) * | 1985-08-16 | 1987-03-24 | Kempe Tomas G | Calcitonin analogs with C-terminal D-amino acid substituents |
JP2753274B2 (ja) | 1988-08-24 | 1998-05-18 | 株式会社三和化学研究所 | モチリン様ポリペプチドの製法並びにそのための組換えdna及び発現用プラスミド |
US5310277A (en) * | 1988-11-22 | 1994-05-10 | Arrestarum Ltd. | Means and net for slowing down and/or stopping the motion of a land vehicle |
JPH0722517B2 (ja) | 1989-08-24 | 1995-03-15 | 株式会社三和化学研究所 | モチリン様ポリペプチドの製法並びにそのための組換えdna及び発現用プラスミド |
US5175146A (en) * | 1989-12-05 | 1992-12-29 | Vical, Inc. | Synthetic calcitonin peptides |
JPH0459795A (ja) | 1990-06-26 | 1992-02-26 | Sanwa Kagaku Kenkyusho Co Ltd | カルシトニン様活性を有するポリペプチド誘導体及びその用途 |
-
1994
- 1994-06-21 JP JP6138618A patent/JPH083196A/ja active Pending
-
1995
- 1995-06-13 EP EP95109138A patent/EP0694561A1/en not_active Withdrawn
- 1995-06-15 US US08/490,669 patent/US5536812A/en not_active Expired - Fee Related
- 1995-06-20 CN CN95107036A patent/CN1120549A/zh active Pending
- 1995-06-21 KR KR1019950016580A patent/KR960000921A/ko not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EP0694561A1 (en) | 1996-01-31 |
JPH083196A (ja) | 1996-01-09 |
US5536812A (en) | 1996-07-16 |
CN1120549A (zh) | 1996-04-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR960000921A (ko) | 칼시토닌 유도체 및 그 용도 | |
ATE311196T1 (de) | Zusammensetzungen geeignet zur kontrollierten freisetzung des hormons gnrh und dessen analoga | |
BR0209709A (pt) | Composições hipotensivas de lipìdio e timolol e métodos de uso das mesmas | |
IL151371A0 (en) | Modified porcine factor viii and pharmaceutical compositions containing the same | |
KR890000101A (ko) | 반월조직의 치료 개선방법 및 치료약제 | |
KR960034219A (ko) | 글루카곤-유사형 인슐린 분비 촉진 착체, 조성물 및 방법 | |
BR9813373A (pt) | Composto, processo para a preparação do mesmo, composição farmacêutica, processo para a preparação da mesma, uso de um composto, e, processos para efetuar imunossupressão e para tratar ou reduzir o risco de uma doença das vias aérias obstrutiva reversìvel em um paciente | |
KR910004187A (ko) | 세트랄린을 사용한 조기사정의 치료방법 | |
DE60000288D1 (de) | Monodisperse formulierungen, die hexamere acylierte insulinanaloge enthalten | |
BR9811755A (pt) | Peptìdeo, processo para o tratamento da obesidade em um animal, uso de um peptìdeo, e, composição farmacêutica | |
ATE218868T1 (de) | Hustenhemmende, theobromine enthaltende zusammensetzungen | |
KR920009846A (ko) | 시클로펩티드 | |
KR880012641A (ko) | 아미노산 유도체 | |
ES2106531T3 (es) | Compuestos de dibenzoxazepina substituidos en 2, 3, 4, 5, 6, 7, 8, 9 y/o 10, composiciones farmaceuticas y metodos de uso. | |
BR9307687A (pt) | Análogos de insulina | |
KR960702847A (ko) | 생물학적 활성의 바소프레신 유사체 | |
KR880013974A (ko) | 합성펩티드와 이를 포함하는 제약학적 조성물 | |
KR927002373A (ko) | 성장 호르몬 분비 활성을 갖는 폴리펩타이드 화합물 | |
ES2146231T3 (es) | Polipeptidos derivados de la endonexina 2 y que presentan una actividad de receptor del virus de la hepatitis b, y su utilizacion en composiciones diagnosticas y farmaceuticas. | |
KR890700606A (ko) | 생물학적 활성분자 | |
DE69808938D1 (de) | Verfahren zur herstellung von pharmazeutischen zusammensetzungen | |
ATE546461T1 (de) | Gnrh analog von nicht-säugertieren und verwendung zur regulierung der fruchtbarkeit und der schwangerschaft | |
ATE311897T1 (de) | Behandlung von multiplersklerose mit einer kombination von interferon und wachstumshormone | |
ATE245998T1 (de) | Somatostatin agoniste zur reduzierung von körpergewicht | |
EP1243595A4 (en) | BH4 FUSIONED POLYPEPTIDES |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |